文献速递胸部肿瘤

靶向NGS揭示非小细胞肺癌免疫检查点抑制剂应答的分子决定因素

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
PubMed 文献 · J Clin Oncol · 2018-01-16

该研究对240例接受抗PD-1/PD-L1治疗的晚期非小细胞肺癌患者进行靶向NGS(MSK-IMPACT)检测,评估肿瘤突变负荷(TMB)、拷贝数改变基因组比例及基因变异与持久临床获益(DCB)的关系。结果显示靶向NGS估算的TMB与全外显子测序高度相关,高TMB与DCB及更长的无进展生存期相关,EGFR和STK11变异与缺乏获益相关,TMB与PD-L1表达独立且联合可进一步富集获益人群。

要点

  • 靶向NGS估算的TMB与全外显子测序高度相关(ρ=0.86;P<.001)。
  • 高TMB患者DCB比例更高、PFS更长,EGFR和STK11变异与缺乏获益相关。
  • TMB与PD-L1表达独立,二者联合可进一步富集免疫治疗获益人群。

核心结论

  • 靶向NGS可准确估算TMB,高TMB提高免疫检查点抑制剂获益可能性,TMB与PD-L1表达独立且联合预测能力更强。

研究设计与样本

  • 回顾性分析240例接受抗PD-1/PD-L1治疗的晚期非小细胞肺癌患者,均经靶向NGS(MSK-IMPACT)检测,并收集详细临床标注和应答数据。
  • 疗效按RECIST 1.1评估,DCB定义为持续>6个月的部分缓解或疾病稳定;对49例患者行全外显子测序以比较TMB量化。

主要发现

  • 靶向NGS估算的TMB与全外显子测序相关性好(ρ=0.86;P<.001)。
  • DCB患者TMB高于无持久获益(NDB)患者(P=.006)。
  • TMB高于第50百分位阈值时DCB更常见(38.6% v 25.1%;P<.001),PFS更长(HR=1.38;P=.024)。
  • 拷贝数改变基因组比例在NDB患者中最高;EGFR和STK11变异与缺乏获益相关。
  • TMB与PD-L1表达为独立变量,TMB联合PD-L1进一步富集获益人群。

关键数值与推荐

  • DCB定义为部分缓解或疾病稳定持续>6个月。
  • TMB高于第50百分位阈值时DCB率为38.6% vs 25.1%(P<.001),PFS的HR为1.38(P=.024)。

临床怎么用

  • 靶向NGS测定的TMB可作为免疫检查点抑制剂获益的预测标志物,高TMB提示更可能获益。
  • EGFR和STK11变异提示可能缺乏免疫治疗获益,决策时需结合这些分子特征。
  • TMB与PD-L1表达独立,联合两者构建多变量预测模型可能提高预测效能。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Treatment of advanced non-small-cell lung cancer with immune checkpoint inhibitors (ICIs) is characterized by durable responses and improved survival in a subset of patients. Clinically available tools to optimize use of ICIs and understand the molecular determinants of response are needed. Targeted next-generation sequencing (NGS) is increasingly routine, but its role in identifying predictors of response to ICIs is not known. Methods Detailed clinical annotation and response data were collected for patients with advanced non-small-cell lung cancer treated with anti-programmed death-1 or anti-programmed death-ligand 1 [anti-programmed cell death (PD)-1] therapy and profiled by targeted NGS (MSK-IMPACT; n = 240). Efficacy was assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and durable clinical benefit (DCB) was defined as partial response/stable disease that lasted > 6 months. Tumor mutation burden (TMB), fraction of copy number-altered genome, and gene alterations were compared among patients with DCB and no durable benefit (NDB). Whole-exome sequencing (WES) was performed for 49 patients to compare quantification of TMB by targeted NGS versus WES. Results Estimates of TMB by targeted NGS correlated well with WES (ρ = 0.86; P < .001). TMB was greater in patients with DCB than with NDB ( P = .006). DCB was more common, and progression-free survival was longer in patients at increasing thresholds above versus below the 50th percentile of TMB (38.6% v 25.1%; P < .001; hazard ratio, 1.38; P = .024). The fraction of copy number-altered genome was highest in those with NDB. Variants in EGFR and STK11 associated with a lack of benefit. TMB and PD-L1 expression were independent variables, and a composite of TMB plus PD-L1 further enriched for benefit to ICIs. Conclusion Targeted NGS accurately estimates TMB and elevated TMB further improved likelihood of benefit to ICIs. TMB did not correlate with PD-L1 expression; both variables had similar predictive capacity. The incorporation of both TMB and PD-L1 expression into multivariable predictive models should result in greater predictive power.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Rizvi H, Sanchez-Vega F, La K, et al. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. J Clin Oncol. 2018. PMID: 29337640. doi:10.1200/JCO.2017.75.3384

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。